Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
Key Highlights
- ➤DAWNZERA cut HAE attack rates 95% over two years in OASISplus patients
- ➤Switch-cohort patients achieved 71% attack-rate reduction after two years
- ➤84% of OASISplus OLE patients remained in the study after two years
- ➤Q8W dosing maintained 95% attack-rate reduction, matching Q4W dosing
- ➤No new safety signals emerged; no serious DAWNZERA-related TEAEs occurred
Expert Statements
Kenneth Newman, Senior vice president, clinical development, Ionis
“People living with hereditary angioedema are faced with a chronic disease and need prophylactic therapy that will provide long-lasting disease control”
Kenneth Newman, Senior vice president, clinical development, Ionis
“These data demonstrate that DAWNZERA achieved durable efficacy and safety, not only when dosed every four weeks but also every eight weeks.”
Kenneth Newman, Senior vice president, clinical development, Ionis
“In our switch study, patients who transitioned to DAWNZERA using a predefined protocol continue to experience lasting reductions in attack rates compared with baseline on their prior therapy.”
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
* DAWNZERA showed sustained HAE attack rate reduction and long-term safety over two years * 71% HAE attack rate reduction maintained after two years on DAWNZERA compared to baseline for patients switching from another long-term prophylactic therapy * Treatment effect maintained regardless of dosing frequency every four or eight weeks Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA(®) (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohorts over two years.
Get started
Create a free account to read the full story.